

Philip D Dunne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1993157/publications.pdf>

Version: 2024-02-01

57
papers

5,756
citations

257357

24
h-index

143943

57
g-index

67
all docs

67
docs citations

67
times ranked

11806
citing authors

#	ARTICLE	IF	CITATIONS
1	QuPath: Open source software for digital pathology image analysis. <i>Scientific Reports</i> , 2017, 7, 16878.	1.6	3,854
2	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. <i>Gut</i> , 2021, 70, 544-554.	6.1	148
3	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4095-4104.	3.2	135
4	The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. <i>Nature Genetics</i> , 2021, 53, 16-26.	9.4	114
5	EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 230-242.	3.2	97
6	AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 164-175.	3.2	95
7	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. <i>Cell Reports</i> , 2014, 7, 1940-1955.	2.9	90
8	Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. <i>Cell Death and Disease</i> , 2014, 5, e1046-e1046.	2.7	77
9	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. <i>Nature Communications</i> , 2017, 8, 15657.	5.8	70
10	Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1426-1441.	1.6	66
11	DNMT1 deficiency triggers mismatch repair defects in human cells through depletion of repair protein levels in a process involving the DNA damage response. <i>Human Molecular Genetics</i> , 2011, 20, 3241-3255.	1.4	63
12	Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. <i>Histopathology</i> , 2018, 73, 327-338.	1.6	63
13	Gremlin1 plays a key role in kidney development and renal fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F1141-F1157.	1.3	58
14	Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. <i>Gut</i> , 2020, 69, 1092-1103.	6.1	52
15	Prospective patient stratification into robust cancer cell intrinsic subtypes from colorectal cancer biopsies. <i>Journal of Pathology</i> , 2018, 245, 19-28.	2.1	49
16	Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study. <i>Histopathology</i> , 2017, 71, 12-26.	1.6	48
17	Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	1.5	45
18	Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2. <i>British Journal of Pharmacology</i> , 2017, 174, 3677-3695.	2.7	38

#	ARTICLE	IF	CITATIONS
19	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. <i>British Journal of Cancer</i> , 2017, 117, 203-209.	2.9	38
20	Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 78932-78945.	0.8	36
21	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 582-591.	1.6	35
22	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 347-352.	2.9	31
23	The Intricate Interplay between Epigenetic Events, Alternative Splicing and Noncoding RNA Deregulation in Colorectal Cancer. <i>Cells</i> , 2019, 8, 929.	1.8	28
24	cudaMap: a GPU accelerated program for gene expression connectivity mapping. <i>BMC Bioinformatics</i> , 2013, 14, 305.	1.2	25
25	QUADrATIC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics. <i>BMC Bioinformatics</i> , 2016, 17, 198.	1.2	25
26	Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition. <i>Journal of Pathology</i> , 2018, 246, 422-426.	2.1	25
27	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. <i>Modern Pathology</i> , 2017, 30, 1287-1298.	2.9	23
28	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17808-17819.	3.3	18
29	Defining the molecular evolution of extrauterine high grade serous carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 305-317.	0.6	17
30	Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapies. <i>BMC Systems Biology</i> , 2015, 9, S4.	3.0	16
31	Standardising RNA profiling based biomarker application in cancer – The need for robust control of technical variables. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 258-272.	3.3	16
32	Connectivity Mapping for Candidate Therapeutics Identification Using Next Generation Sequencing RNA-Seq Data. <i>PLoS ONE</i> , 2013, 8, e66902.	1.1	16
33	PICan: An integromics framework for dynamic cancer biomarker discovery. <i>Molecular Oncology</i> , 2015, 9, 1234-1240.	2.1	15
34	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 36632-36644.	0.8	15
35	An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. <i>Cell Death and Differentiation</i> , 2022, 29, 806-817.	5.0	15
36	The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers. <i>Oncotarget</i> , 2015, 6, 12763-12773.	0.8	14

#	ARTICLE	IF	CITATIONS
37	Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. <i>Clinical Cancer Research</i> , 2022, 28, 4056-4069.	3.2	14
38	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 288-300.	3.2	13
39	Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1627-1639.	1.9	13
40	FLINO: a new method for immunofluorescence bioimage normalization. <i>Bioinformatics</i> , 2022, 38, 520-526.	1.8	12
41	Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt. <i>Oncotarget</i> , 2019, 10, 4630-4639.	0.8	12
42	Punctate γ -H2AX mismatch repair immunostaining in colorectal cancer. <i>Histopathology</i> , 2019, 74, 795-797.	1.6	11
43	Development of a semi-automated method for tumour budding assessment in colorectal cancer and comparison with manual methods. <i>Histopathology</i> , 2022, 80, 485-500.	1.6	11
44	Embracing an integrative approach to tissue biomarker research in cancer: Perspectives and lessons learned. <i>Briefings in Bioinformatics</i> , 2017, 18, bbw044.	3.2	9
45	Downregulation of PPAR α during Experimental Left Ventricular Hypertrophy is Critically Dependent on Nox2 NADPH Oxidase Signalling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4406.	1.8	9
46	KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies. <i>Oncotarget</i> , 2017, 8, 3206-3225.	0.8	9
47	<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancer. <i>Oncotarget</i> , 2018, 9, 13834-13847.	0.8	9
48	Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1724-1734.	1.9	7
49	ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA. <i>Cancer Research</i> , 2019, 79, 2072-2075.	0.4	6
50	IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer. <i>Cell Death Discovery</i> , 2017, 3, 17050.	2.0	5
51	Comment on "Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes". <i>British Journal of Cancer</i> , 2021, 124, 1175-1176.	2.9	5
52	Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional data. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	4
53	Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer. <i>Gut</i> , 2022, 71, 2502-2517.	6.1	4
54	Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression. <i>JCO Precision Oncology</i> , 2018, 2, 1-17.	1.5	3

#	ARTICLE	IF	CITATIONS
55	Intratumoural Epigenetic Heterogeneity in Early Invasive Colorectal Cancer: A Prognostic Imprint?. <i>Gastroenterology</i> , 2017, 152, 1622-1623.	0.6	2
56	Response to Park <i>et al</i> . reply to "Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study". <i>Histopathology</i> , 2017, 71, 327-329.	1.6	1
57	Prognosis following surgical resection versus local excision of stage pT1 colorectal cancer: A population-based cohort study. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2020, 18, 65-74.	0.8	1